<< Вернуться к списку статей журнала

Том 3 №2 2001 год - Нефрология и диализ

Маркеры прогнозирования эффективности терапии преднизолоном у детей с первичным нефротическим синдромом (Обзор литературы)

Мурадов С.Г.

Аннотация: Первичный (идиопатический) нефротический синдром у детей - это клинико-лабораторный симптомокомплекс, характеризующийся протеинурией, гипо- и диспротеинемией, гиперлипидемией и отеками и связанный с первичным заболеванием собственно клубочков почек [11]. Среди всех детей с нефротическим синдромом 90% приходится на первичный нефротический синдром [24].

Для цитирования: Мурадов С.Г. Маркеры прогнозирования эффективности терапии преднизолоном у детей с первичным нефротическим синдромом (Обзор литературы). Нефрология и диализ. 2001. 3(2):205-211. doi:

Весь текст

Ключевые слова: первичный нефротический синдром, гормонорезистентность, лимфоциты, интерлейкины, глюкокортикоидные рецепторы

Список литературы:

1. Багдасарова И.В. Интегральные клинико-патогенетические принципы выбора терапии, прогнозирование и оценка ее эффективности при гломерулонефрите у детей: Автореф. дисс.. д-ра мед. наук. Киев., 1990; 42.
2. Галактионов В.Г. Иммунология: Учебник. М.: Изд-во МГУ, 1998; 480.
3. Доломанова О.Е. Иммуноцитологические особенности и чувствительность лимфоцитов к цитотоксическим препаратам у детей с первичным хроническим гломерулонефритом: Дисс.. канд. мед. наук. М., 1990; 190.
4. Игнатова М.С., Курбанова Э.Г. Иммуносупрессивная терапия нефротического синдрома у детей. М.: РППП, 2000; 103.
5. Коровина Н.А., Гаврюшова Л.П., Захарова И.Н., Мумладзе Э.Б. Протокол диагностики и лечения нефротической формы гломерулонефрита у детей. М.: ООО «Изд-во «Посад», 2000; 60.
6. Копылева О.Д. Варианты гормонорезистентного нефротического синдрома у детей и мембранотропные средства в его лечении: Дисс.. канд. мед. наук. М., 1989; 160.
7. Лебедев К.А., Понякина И.Д. Иммунограмма в клинической практике. М.: Наука, 1990; 224.
8. Мазуров В.И., Кузнецов И.А., Шелухин В.А. Система мононуклеарных фагоцитов и возможности иммуносупрессии при хроническом гломерулонефрите. Сборник трудов III нефрологического Санкт-Петербургского нефрологического семинара, 26 мая - 3 июня 1995, г. Санкт-Петербург, Россия. - Спб.: ТНА, 1995; 190-195.
9. Москалева Е.С. Клинико-патогенетическая характеристика нефротического синдрома у детей с атопическими проявлениями: Автореф. дисс.. канд. мед. наук. М., 1989; 26.
10. Москалева Е.С., Длин В.В., Харина Е.А., Курбанова Э.Г. Принципы лечения первичного нефротического синдрома у детей глюкокортикоидами и цитостатиками // Сб. статей «Современные методы диагностики и лечения нефро-урологических заболеваний у детей» Материалы I ежегодного конгресса. Москва 5-7 октября 1998 г. М., 1998; 81-86.
11. Савенкова Н.Д., Папаян А.В. Нефротический синдром в практике педиатра: Руководство для врачей. СПб.: Эскулап, 1999; 256.
12. Сасу Б.И., Мухин Н.А., Ляшко В.Н., Фрейдин М.И. Глюкокортикоидные рецепторы и прогноз глюкокортикоидной терапии нефритов // Клин. Мед. 1984; 4: 75-83.
13. Сергеева Т.В., Цыгин А.Н. Гломерулонефрит и нефротический синдром. Материалы второго съезда педиатров-нефрологов России, Москва 11-13 октября 2000 г. М., 1998; 10-11.
14. Стефани Д.В., Вельтищев Ю.Е. Клиническая иммунология и иммунопатология детского возраста: Руководство для врачей. М.: Медицина, 1996; 384.
15. Фрейдлин И.С. Дефекты цитокиновой сети и принципы их коррекции // Иммунология. 1998; 6: 23-25.
16. Цыгин А.Н. Патогенетические основы первичного нефротического синдрома и лечения его стероидорезистентных вариантов у детей: Автореф. дисс.. д-ра мед. наук. М., 1996; 42.
17. Al-Azzawi Y.H., Altawil N.G., Alshamaa I.A. Lymphocyte transformation test in adult patients with minimal change nephrotic syndrome. Scand. J. Immunol., 1994; 40: 277-280.
18. Alper C.A., Rosen F.S. Inherited deficiencies of complement proteins in man. Springer Semin. Immunopathol., 1984; 7; 3: 251-61.
19. Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms [editorial]. Clin Sci (Colch)., 1998; 94: 557-72.
20. Botto M. C1q knock-out mice for the study of complement deficiency in autoimmune disease. Exp. Clin. Immunogenet., 1998; 15: 231-4.
21. Botto M., Dell’Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., Loos M., Pandolfi P.P., Walport M.J. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet., 1998; 19: 56-9.
22. Bray P.J., Du B., Mejia V.M., Hao S.C., Deutsch E., Fu C., Wilson R.C., Hanauske-Abel H., McCaffrey T.A. Glucocorticoid resistance caused by reduced expression of the glucocorticoid receptor in cells from human vascular lesions. Arterioscler. Thromb. Vasc. Biol., 1999; 19: 1180-9.
23. Brodehl J. Conventional therapy for idiopathic nephrotic syndrome in children. Clin. Nephrol., 1991; 35 (Suppl. 1): S8-S15.
24. Cameron J.S. Glomerulonephritis-1974. Ir. J. Med. Sci., 1975; (Suppl.): 72-80.
25. Cassatella M.A. The neutrophil: one of the cellular targets of interleukin-10. Int. J. Clin. Lab. Res., 1998; 28: 148-61.
26. Cassatella M.A., Meda L., Bonora S., Ceska M., Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cyto-kines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J. Exp. Med., 1993; 178: 2207-11.
27. Cho B.-S., Yoon S.-R., Jang J.-Y., Pyun K.-H., Lee C.-E. Up-regulation of interleukin-4 and CD23/Fc.RII in minimal change nephrotic syndrome. Pediatr. Nephrol., 1999; 13: 199-204.
28. Daniel V., Trautmann Y., Konrad M., Nauir A., Scharer K. T-lymphocyte populations, cytokins and other growth factors in serum and urine of children with idiopathic nephrotic syndrome. Clinical Nephrology, 1997; 47: 289-297.
29. de Lange P., Koper J.W., Huizenga N.A., Brinkmann A.O., de Jong F.H., Karl M., Chrousos G.P., Lamberts S.W. Differential hormone-dependent transcriptional activation and -repression by naturally occurring human glucocorticoid receptor variants. Mol. Endocrinol., 1997; 11: 1156-64.
30. de Waal Malefyt R., Abrams J., Bennett B., Figdor C.G., de Vries J.E. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med., 1991; 174: 1209-20.
31. Deleuran B., Iversen L., Kristensen M., Field M., Kragballe K., Thestrup-Pedersen K., Stengaard-Pedersen K. Interleukin-8 secretion and 15-lipoxygenase activity in rheumatoid arthritis: in vitro anti-inflammatory effects by interleukin-4 and interleukin-10, but not by interleukin-1 receptor antagonist protein. Br. J. Rheumatol., 1994; 33: 520-5.
32. DeRijk R., Sternberg E.M. Corticosteroid resistance and disease. Ann. Med., 1997; 29: 79-82.
33. Dohi K., Morita H., Ogawa S., Hirayama T., Yamada H., Ishikawa H. Production of interleukin 2 (IL-2) and responsiveness to IL-2 of peripheral blood lymphocytes in minimal change nephrotic syndrome. Jpn. J. Med., 1991; 30: 396-401.
34. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol., 1991; 147: 3815-22.
35. Forehand J.R., Johnston R.B. Chronic granulomatous disease: newly defined molecular abnormalities explain disease variability and normal phagocyte physiology. Curr. Opin. Pediatr., 1995; 7: 126.
36. Franchimont D., Martens H., Hagelstein M.T., Louis E., Dewe W., Chrousos G.P., Belaiche J., Geenen V. Tumor necrosis factor alpha decreases, and interleukin-10 increases, the sensitivity of human monocytes to dexamethasone: potential regulation of the glucocorticoid receptor. J. Clin. Endocrinol. Metab., 1999; 84: 2834-9.
37. Fukuda R., Horiki T., Sasao T., Kawada H., Ichikawa Y. Modulation of peripheral blood lymphocyte subsets during methylprednisolone pulse therapy. Tokai J. Exp. Clin. Med., 1996; 21: 77-88.
38. Garin E.H., Blanchard D.K., Matsushima K., Djeu J.Y. IL-8 production by peripheral blood mononuclear cells in nephrotic patients. Kidney Int., 1994; 45: 1311-7.
39. Garin E.H., Laflam P., Chandler L. Anti-interleukin 8 antibody abolishes effects of lipoid nephrosis cytokine. Pediatr. Nephrol., 1998; 12: 381-5.
40. Garin E.H., West L., Zheng W. Effect of interleukin-8 on glome-rular sulfated compounds and albuminuria. Pediatr. Nephrol., 1997; 11: 274-9.
41. Gruol D.J., Vo Q.D., Zee M.C. Profound differences in the transport of steroids by two mouse P-glycoproteins. Biochem. Pharmacol., 1999; 58; 7: 1191-9.
42. Hamid Q.A., Wenzel S.E., Hauk P.J., Tsicopoulos A., Wallaert B., Lafitte J.J., Chrousos G.P., Szefler S.J., Leung D.Y. Increased glucocorticoid receptor beta in airway cells of glucocorticoid-insensitive asthma. Am. J. Respir. Crit. Care Med., 1999; 159: 1600-4.
43. Hara S., Halicka H.D., Bruno S., Gong J., Traganos F., Darzynkiewicz Z. Effect of protease inhibitors on early events of apoptosis. Exp. Cell Res., 1996; 223: 372-84.
44. Hewitt I.K., House A.K., Potter J.M., Kinnear B.F. Altered in vitro lymphocyte response in childhood nephrotic syndrome. Pediatr. Nephrol., 1992; 6: 464-6.
45. Hogue D.L., Kerby L., Ling V. A mammalian lysosomal membrane protein confers multidrug resistance upon expression in Saccharomyces cerevisiae. J. Biol. Chem., 1999; 274: 12877-82.
46. Honda M., Orii F., Ayabe T., Imai S., Ashida T., Obara T., Kohgo Y. Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology, 2000; 118: 859-66.
47. Hulton S.A., Shah V., Byrne M.R., Morgan G., Barratt T.M., Dillon M.J. Lymphocyte subpopulations, interleukin-2 and interleukin-2 receptor expression in childhood nephrotic syndrome. Pediatr. Nephrol., 1994; 8: 135-9.
48. Iida S., Fujii H., Moriwaki K. Familial cortisol resistance and mutations of the glucocorticoid receptor gene. Nippon Rinsho, 1998; 56: 1887-91.
49. Kasama T., Strieter R.M., Lukacs N.W., Burdick M.D., Kunkel S.L. Regulation of neutrophil-derived chemokine expression by IL-10. J. Immunol., 1994; 152: 3559-69.
50. Kobayashi Y., Yoshikawa N., Nakamura H. T-cell subpopulations in childhood nephrotic syndrome. Clin. Nephrol., 1994; 41: 253-258.
51. Koper J.W., Stolk R.P., de Lange P., Huizenga N.A., Molijn G.J., Pols H.A., Grobbee D.E., Karl M., de Jong F.H., Brinkmann A.O., Lamberts S.W. Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum. Genet., 1997; 99: 663-8.
52. Kwong K.Y., Jones C.A., Cayabyab R., Lecart C., Khuu N., Rhandhawa I., Hanley J.M., Ramanathan R., deLemos R.A., Minoo P. The effects of IL-10 on proinflammatory cytokine expression (IL-1beta and IL-8) in hyaline membrane disease (HMD). Clin. Immunol. Immunopathol., 1998; 88: 105-13.
53. Lagrue G., Laurent J., Hirbec G., Ansquer J.C., Noirot C., Laurent G., Nebout T., Kestenbaum S. Serum IgE in primary glomerular diseases. Nephron, 1984; 36: 5-9.
54. Lagrue G., Laurent J. Is lipoid nephrosis an «allergic» disease? Transplant. Proc., 1982; 14: 485-8.
55. Lane S.J., Lee T.H. Mechanisms of corticosteroid resistance in asthmatic patients. Int. Arch. Allergy Immunol., 1997; 113: 193-5.
56. Lange K. The future of nephrologic research: significance and urgent problems. Clin. Nephrol., 1984; 21: 82-5.
57. Lanza L., Scudeletti M., Puppo F., Bosco O., Peirano L., Filaci G., Fecarotta E., Vidali G., Indiveri F. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin. Exp. Immunol., 1996; 103: 482-90.
58. Larsson S., Lofdahl C.G., Linden M. IL-2 and IL-4 counteract budesonide inhibition of GM-CSF and IL-10, but not of IL-8, IL-12 or TNF-alpha production by human mononuclear blood cells. Br. J. Pharmacol., 1999; 127: 980-6.
59. Leung D.Y.M., Hamid Q., Vottero A., Szefler S.J., Surs W., Minshall E., Chrousos G.P., Klemm D.J. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J. Exp. Med., 1997; 186: 1567-74.
60. Leung D.Y., de Castro M., Szefler S.J., Chrousos G.P. Mechanisms of glucocorticoid-resistant asthma. Ann. N. Y. Acad. Sci., 1998; 840: 735-46.
61. Matsumoto K. Decreased production of interleukin-1 by monocytes from patients with lipoid nephrosis. Clin. Nephrol., 1989; 31: 292-6.
62. Matsumoto K., Ohi H., Kanmatsuse K. Interleukin 12 upregulates the release of vascular permeability factor by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron, 1998; 78: 403-9.
63. Matsumoto K. Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis. Nephron, 1997; 75: 154-9.
64. Matsumoto K. Interleukin-1 production by monocytes from patients with glomerulonephritis after stimulation in vitro with so-luble immune complexes. Clin. Nephrol., 1991; 36: 267-73.
65. Matsumoto K. Spontaneous and lipopolysaccharide-stimula-ted secretion of cytokines by peripheral blood monocytes in IgA nephropathy is inhibited by interleukin-10. Nephron, 1996; 73: 305-9.
66. Matsumoto K., Ohi H., Kanmatsuse K. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Nephron, 1997; 77: 212-8.
67. Matsumoto K., Osakabe K., Katayama H., Hatano M. In vitro lymphocyte dysfunction in lipoid nephrosis mediated by suppressor cells. Nephron, - 1982; 32: 270-272.
68. Michel G., Mirmohammadsadegh A., Olasz E., Jarzebska-Deussen B., Muschen A., Kemeny L., Abts H.F., Ruzicka T. Demonstration and functional analysis of IL-10 receptors in human epidermal cells: decreased expression in psoriatic skin, down-modulation by IL-8, and up-regulation by an antipsoriatic glucocorticosteroid in normal cultured keratinocytes. J. Immunol., 1997; 159: 6291-7.
69. Miller A.H., Pariante C.M., Pearce B.D. Effects of cytokines on glucocorticoid receptor expression and function. Glucocorticoid resistance and relevance to depression. Adv. Exp. Med. Biol., 1999; 461: 107-16.
70. Moorthy A.V., Zimmerman S.W., Burkholder P.M. Inhibitors of lymphocyte blastogenesis by plasma of patients with minimal change nephrotic syndrome. Lancet, 1976; 1: 1160-1162.
71. Neuhaus T.J., Wadhwa M., Callard R., Barratt T.M. Increased IL-2, IL-4 and interferon-gamma (IFN-gamma) in steroid-sensitive nephrotic syndrome. Clin. Exp. Immunol., 1995; 100: 475-9.
72. New M.I., Nimkarn S., Brandon D.D., Cunningham-Rundles S., Wilson R.C., Newfield R.S., Vandermeulen J., Barron N., Russo C., Loriaux D.L., O’Malley B. Resistance to several steroids in two sisters. J. Clin. Endocrinol. Metab., 1999; 84: 4454-64.
73. Oakley R.H., Jewell C.M., Yudt M.R., Bofetiado D.M., Cidlowski J.A. The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J. Biol. Chem., 1999; 274: 27857-66.
74. Pariante C.M., Pearce B.D., Pisell T.L., Sanchez C.I., Po C., Su C., Miller A.H. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrino-logy, 1999; 140: 4359-66.
75. Pountain G.D., Keogan M.T., Hazleman B.L., Brown D.L. Effects of single dose compared with three days’ prednisolone treatment of healthy volunteers: contrasting effects on circulating lymphocyte subsets. J. Clin. Pathol., 1993; 46: 1089-92.
76. Ramos R.A., Meilandt W.J., Wang E.C., Firestone G.L. Dysfunctional glucocorticoid receptor with a single point mutation ablates the CCAAT/enhancer binding protein-dependent growth suppression response in a steroid-resistant rat hepatoma cell variant. FASEB J., 1999; 13: 169-80.
77. Sakurai M., Muso E., Matushima H., Ono T., Sasayama S. Rapid normalization of interleukin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome. Kidney Int., 1999; 71 (Suppl.): S210-2.
78. Sarhan A.A., Bakr A.M., El-Shenawy F., Shokeir M.A., Hammad A.M., Yosef M.R., Seleim W.A. Study of interleukin-8 in children with primary nephrotic syndrome. Pediatr. Nephrol., 1999; 13: 62.
79. Saxena S., Mittal A., Andal A. Pattern of interleukins in minimal-change nephrotic syndrome of childhood. Nephron, 1993; 65: 56-61.
80. Scudeletti M., Lanza L., Monaco E., Monetti M., Puppo F., Filaci G., Indiveri F. Immune regulatory properties of corticosteroids: prednisone induces apoptosis of human T lymphocytes following the CD3 down-regulation. Ann. N. Y. Acad. Sci., 1999; 876: 164-79.
81. Seki M., Ushiyama C., Seta N., Abe K., Fukazawa T., Asakawa J., Takasaki Y., Hashimoto H. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum., 1998; 41: 823-30.
82. Shahidi H., Vottero A., Stratakis C.A., Taymans S.E., Karl M., Longui C.A., Chrousos G.P., Daughaday W.H., Gregory S.A., Plate J.M. Imba-lanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. Biochem. Biophys. Res. Commun., 1999; 254: 559-65.
83. Sleasman J.W. The association between immunodeficiency and the development of autoimmune disease. Adv. Dent. Res., 1996; 10: 57-61.
84. Sousa A.R., Lane S.J., Cidlowski J.A., Staynov D.Z., Lee T.H. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform. J. Allergy Clin. Immunol., 2000; 105: 943-50.
85. Stefanovic V, Golubovic E, Mitic-Zlatkovic M, Vlahovic P, Jovanovic O, Bogdanovic R. Interleukin-12 and interferon-gamma production in childhood idiopathic nephrotic syndrome. Pediatr. Nephrol., 1998; 12: 463-6.
86. Tan J., Deleuran B., Gesser B., Maare H., Deleuran M., Larsen C.G., Thestrup-Pedersen K. Regulation of human T lymphocyte chemotaxis in vitro by T cell-derived cytokines IL-2, IFN-gamma, IL-4, IL-10, and IL-13. J. Immunol., 1995; 154: 3742-52.
87. Topaloglu R., Bakkaloglu A., Slingsby J.H., Mihatsch M.J., Pascual M., Norsworthy P., Morley B.J., Saatci U., Schifferli J.A., Walport M.J. Molecular basis of hereditary C1q deficiency associated with SLE and IgA nephropathy in a Turkish family. Kidney Int., 1996; 50: 635-42.
88. Vicioso M.A., Garaud J.J., Reglier-Poupet H., Lebeaut A., Gougerot-Pocidalo M.A., Chollet-Martin S. Moderate inhibitory effect of interleukin-10 on human neutrophil and monocyte chemotaxis in vitro. Eur. Cytokine Netw., 1998; 9: 247-53.
89. Walport M.J., Davies K.A., Botto M. C1q and systemic lupus erythematosus. Immunobiology, 1998; 199: 265-85.
90. Webb N.J., Lewis M.A., Iqbal J. et al. Childhood steroid sensitive nephrotic syndrome: Does the histology matter? Am. J. Kidney Dis., 1996; 27: 484-488.
91. Welch T.R., McAdams A.J., Beischel L.S. Glomerulonephritis associated with complete deficiency of the fourth component of complement. Response to intravenous immunoglobulin. Arthritis Rheum., 1995; 38: 1333-7.
92. Wu T.H., Tsai C.Y., Yang W.C. Excessive expression of the tumor necrosis factor-alpha gene in the kidneys of patients with membranous glomerulonephritis. Chung Hua I Hsueh Tsa Chih (Taipei), 1998; 61: 524-30.
93. Yano N., Endoh M., Naka R., Takemura F., Nomoto Y., Sakai H. Altered synthesis of interferon-gamma and expression of interferon-gamma receptor by peripheral blood mononuclear cells from patients with IgA nephropathy and non-IgA proliferative glomerulonephritis. J. Clin. Immunol., 1996; 16: 71-9.
94. Yap H.K., Cheung W., Murugasu B., Sim S.K., Seah C.C., Jordan S.C. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J. Am. Soc. Nephrol., 1999; 10: 529-37.
95. Zoch-Zwiertz W., Wiercinski K., Swierz K., Wasilewska A. Serum IgE, interleukine-2 and 4 and their soluble receptors in children with nephrotic syndrome. Abstr. 11th Congress of IPNA, London, 1998; 17: 103.

Другие статьи по теме

• Активность апоптоза лимфоцитов при хроническом гломерулонефрите
• Состояние иммунной системы при идиопатическом нефротическом синдроме (Лекция)